A Placebo-controlled Phase IIa Study of Orally Administered BGC20-0134/Pleneva TM (Structured Lipid) in Patients With RRMS
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs BGC 200134 (Primary)
- Indications Multiple sclerosis
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors BTG
- 09 Aug 2017 This trial has been Discontinued in Belgium, according to European Clinical Trials Database record.
- 15 Mar 2012 This trial is recruiting in Belgium, France and has discontinued in Germany.
- 05 Oct 2011 Results from patients who have completed the open-label extension are being analysed.